The effect of PO43--P concentration on sludge settleability and nutrients removal performance.

In order to explore the effect of influent PO43--P concentration on the relationship of phosphorus remove performance and sludge settleability, three sequencing batch reactors (SBRs) operated as anaerobic/aerobic mode were used to treat wastewater with different PO43--P concentrations (same COD), and the organic loading rate (OLR) was changed through adjusting the anaerobic (aerobic) duration. The sludge settleability, nutrients removal, and microorganism species were investigated. The results showed that when the influent PO43--P were 4.3 mg·L-1 and 8.6 mg·L-1, increasing the OLR through decreasing aerobic duration could significantly improve sludge settleability, while decreasing anaerobic duration could not. It was found that increase the OLR could promote the denitrification compete for carbon sources with phosphorus release process by inhibiting the accumulation of NO2--N, leading to the decrease of phosphorus removal ability. When the influent PO43--P was 17.2 mg·L-1, sufficient nitrification was beneficial to enrich denitrifying phosphorus accumulating bacteria (DPAO), and the activities of Thauera and Flavobacterium (DPAO) were stronger. Therefore, increasing influent PO43--P concentration and reducing aerobic duration could help phosphorus accumulating bacteria (PAO) compete with denitrification for COD and enrich DPAO, thus reducing carbon source consumption.

Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells.

To study the agricultural production of biosimilar antibodies, trastuzumab (Herceptin) was expressed in Nicotiana benthamiana using the magnICON viral-based transient expression system. Immunoblot analyses of crude plant extracts revealed that trastuzumab accumulates within plants mostly in the fully assembled tetrameric form. Purification of trastuzumab from N. benthamiana was achieved using a scheme that combined ammonium sulfate precipitation with affinity chromatography. Following purification, the specificity of the plant-produced trastuzumab for the HER2 receptor was compared with Herceptin and confirmed by western immunoblot. Functional assays revealed that plant-produced trastuzumab and Herceptin have similar in vitro antiproliferative effects on breast cancer cells that overexpress HER2. Results confirm that plants may be developed as an alternative to traditional antibody expression systems for the production of therapeutic mAbs.